Vertex Reports Strong Q4 & FY25 Results, Positive 2026 Guidance, and Initiates Povetacicept BLA Filing

summarizeSummary

Vertex Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, provided optimistic 2026 revenue guidance, and announced significant pipeline progress including the initiation of a BLA filing for povetacicept in IgA nephropathy.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Results

  Vertex reported a 10% increase in Q4 2025 total revenue to $3.19 billion and a 9% increase in full year 2025 total revenue to $12.0 billion, driven by CF therapies and new product launches. GAAP net income for FY25 was $4.0 billion, a significant turnaround from a net loss in FY24.

• Positive Full Year 2026 Revenue Guidance

  The company provided full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, indicating continued growth. Non-CF products, including CASGEVY and JOURNAVX, are expected to contribute $500 million or more in revenue.

• Povetacicept BLA Filing for IgAN Initiated

  Vertex initiated the rolling Biologics License Application (BLA) filing for U.S. accelerated approval of povetacicept in IgA nephropathy, with completion expected in the first half of 2026. The FDA has granted Breakthrough Therapy Designation and a priority review voucher is being used.

• Significant Progress Across CF and Non-CF Product Launches

  The CF portfolio continues to expand with positive ALYFTREK data in young children. CASGEVY generated $116 million in FY25 revenue from 64 patient infusions, and JOURNAVX saw over 550,000 prescriptions filled, securing broad commercial coverage.

auto_awesomeAnalysis

Vertex Pharmaceuticals delivered robust financial performance for the fourth quarter and full year 2025, exceeding prior year results with significant revenue and net income growth. The company also provided optimistic full year 2026 revenue guidance, projecting continued expansion driven by its cystic fibrosis franchise and increasing contributions from non-CF products like CASGEVY and JOURNAVX. A key highlight is the initiation of the rolling Biologics License Application (BLA) filing for povetacicept in IgA nephropathy, which has Breakthrough Therapy Designation and is on an accelerated review timeline, signaling a major potential new market entry. While the T1D program experienced a temporary manufacturing-related postponement, the overall pipeline demonstrated broad progress, reinforcing the company's diversification strategy and long-term growth prospects.